Bruker Corp designs & manufactures proprietary life science & materials research systems & associated products that serve multiple customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology & in-vitro diagnostics. BSI Life Science reports under two groups: Bruker BioSpin Group & Bruker CALID Group. The Bruker BioSpin comprises the Bruker Magnetic Resonance & Preclinical Imaging divisions, which designs, manufactures & distributes enabling life science tools based on the magnetic resonance technology. The Bruker CALID comprises the Bruker Daltonics & primarily designs, manufactures & distributes life-science mass spectrometry instruments that can be integrated with other sample preparation or chromatography instruments. BSI Nano designs, manufactures & distributes advanced X-ray instruments to determine the characteristics of matter & the three-dimensional structure of molecules....
+See More2019-04-13 14:28:00 Saturday ET
Saudi Aramco unveils the financial secrets of the most profitable corporation in the world. In its recent public bond issuance prospectus, Aramco offers the
2019-08-07 08:32:00 Wednesday ET
Our fintech finbuzz analytic report shines fresh light on the current global economic outlook. As of Summer-Fall 2019, the current analytic report focuses o
2019-11-23 08:33:00 Saturday ET
MIT financial economist Simon Johnson rethinks capitalism with better key market incentives. Johnson refers to the recent Business Roundtable CEO statement
2023-06-19 10:31:00 Monday ET
A brief biography of Dr Andy Yeh (PhD, MFE, MMS, BMS, FRM, and USPTO patent accreditation) Dr Andy Yeh is responsible for ensuring maximum sustainable me
2017-01-11 11:38:00 Wednesday ET
Thomas Piketty's recent new book *Capital in the Twenty-First Century* frames income and wealth inequality now as a global economic phenomenon. When
2017-11-24 08:41:00 Friday ET
Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode? As its prices skyrocket, bankers, pundits, and investors increasingly take side